Amanda Wilhelm, PhD

Deutetrabenazine Reduces Severe Tardive Dyskinesia Movements in a 3-year Open-Label Extension Trial

Background: There are no established treatment guidelines for tardive dyskinesia (TD) based on movement severity. The 12-week ARM-TD and AIM-TD studies in TD patients with baseline Abnorm...

Joseph Bona , MD;

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Nayla Chaijale , PhD;

Mark Forrest Gordon , MD;

10/18/2020

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintenance in Patients With Tardive Dyskinesia

Background: Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly based on dyskinesia control and tolerability. This analysis compared the safety ...

Nayla Chaijale , PhD;

Alexander Send , PhD;

Juha-Matti Savola , MD, PhD;

Mark Forrest Gordon , MD;

Amanda Wilhelm , PhD;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

10/08/2020

Analysis of AIMS Global Judgment Components (Items 8–10) in Patients With TD: Results From the ARM-TD and AIM-TD Studies

Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was...

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Rolf T. Hansen , PhD;

Juha-Matti Savola , MD, PhD;

Maria Wieman , MPH;

Nicholas Gross , MS;

11/22/2019